Kowalzick L, Ziegler H
Photoallergic contact dermatitis from topical diclofenac in Solaraze gel. [Journal Article]
Contact Dermatitis 2006 Jun; 54(6):348-9.
Solaraze((R)) gel (Shire Deutschland GmbH & Co. KG, Cologne, Germany) containing 3% diclofenac has been licensed in 2001 as a topical treatment for actinic keratoses. It is commonly used in dermatological practice. Undesirable effects are believed to be rare but include pruritus, paresthesia and application-site reactions (dry skin, rash, erythema, contact dermatitis and vesicobullous eruptions). Recently, a few cases of contact dermatitis due to three different allergens including diclofenac have been reported (1,2).
More from this journal |
